Three dimensional conformal radiotherapy / intensity modulated radiotherapy alone vs three dimensional conformal therapy / intensity modulated radiotherapy plus adjuvant hormonal therapy in localized T1b-c, T2a, N0, M0 prostatic carcinoma. A phase III randomized study
Phase of Trial: Phase III
Latest Information Update: 15 Sep 2016
At a glance
- Drugs Bicalutamide (Primary) ; Goserelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 03 Jun 2009 New source identified and integrated (United Kingdom Clinical Research Network recprd no. 871).
- 03 Jun 2009 Planned number of patients changed from 800 to 820 as reported by United Kingdom Clinical Research Network.